JD Health

Objective

Convert a free health consultation audience into purchases on JD's pharmacy platform, chaining triage, teleconsultation, testing and medicine purchase inside a single conversation. Management says it then wants to turn this into a business line of its own, with agreements already signed, but publishes no revenue figure attributed to the deployment.

The deployment

JD Health runs the largest online medicine sales platform in China. Dr. Dawei is its consumer-facing doctor agent: the user asks a health question in the app, the agent triages it, runs a consultation-style exchange, reads a test report if needed, then points to a product in the pharmacy catalog or to a doctor at the group's online hospital. The agent was presented on September 25, 2025 among the ten or so agents of AI Hospital 1.0, all built on the in-house medical model Jingyi Qianxun, whose 2.0 version was unveiled the same day. JD Health describes this architecture as a chain running from triage to consultation, testing and medicine purchase. In the first half of 2026, Dr. Dawei gained a long-term health record memory, which supports follow-up between two exchanges instead of a one-off answer. The half-year report states that the number of users served by the agent rose nearly fourfold year over year during the 618 festival, and the earnings call ties that growth to better conversion into product purchases. Cumulatively, the agent has logged several hundred million interactions, a 98% favorable rating, and nearly seven users out of ten coming from tier 3 cities or below. One point stays open: the only figure attached to the deployment is this audience growth. Management says it has signed commercialization agreements for Dr. Dawei and sees a clear path, without publishing revenue, basket size or ARPU. The rise of more than 20% in the number of advertising merchants, cited on the same call, measures JD Health's advertising platform and is not presented as an effect of the agent.

Results Proof A

The central figure comes from the August 13, 2026 earnings call on first-half results, and it is corroborated by two established press outlets relaying the half-year report (Science and Technology Daily, China News Service). Limit to accept: only the agent's audience growth is quantified and attributed to the deployment. The monetization effect stays declarative (commercialization agreements signed, clear path ahead), with no published revenue or basket size, and the rise of more than 20% in advertising merchants measures the advertising platform, not Dr. Dawei. Axis classification: this case is filed under activation_conversion rather than monetization, because the only effect measured and attributed to the deployment concerns audience and routing toward purchase. Monetization of Dr. Dawei is announced, not yet quantified; filing it under monetization would have filled an empty cross-section with an unproven result.

1. 1
   Entry through the health question customer

   The user describes a symptom or uploads a test report in the JD Health app.

2. 2
   Triage and exchange AI

   Dr. Dawei, built on the Jingyi Qianxun model, routes the request, runs the consultation-style exchange and reads the documents provided.

3. 3
   Record recall AI

   The health record memory added in the first half of 2026 makes it possible to pick up the user's history from one exchange to the next, instead of starting over.

4. 4
   Move to action AI

   The exchange leads to a product in the pharmacy catalog, a test, or a handoff to a doctor at the group's online hospital.

5. 5
   Human relay human

   Doctors at the online hospital take over whatever falls outside the agent's scope, in particular anything that requires a prescription.